Metabolic and Epigenetic Reprogramming Driven by H3K18la Modifications in Aggressive Bladder Cancer Linked to Glycolysis

Overview

This study identifies a significant correlation between elevated histone lactylation (H3K18la) and glycolytic activity in bladder cancer. Inhibition of glycolysis or lactate dehydrogenase A (LDHA) knockdown demonstrated anti-tumor effects in bladder cancer models.

Background

Bladder cancer (BC) is characterized by high aggressiveness and poor survival rates. Metabolic reprogramming, particularly through glycolysis, is observed in the tumor's aggressive behavior. The study highlights histone lactylation as an epigenetic modification linked to metabolic changes in BC.

Data Highlights

No numerical data available.

Key Findings

• Increased glycolytic activity and histone lactylation (H3K18la) correlate with poor prognosis in BC patients.
• Inhibition of glycolysis or LDHA knockdown suppresses BC growth in vitro and in vivo.
• Histone lactylation is associated with the expression of oncogenic genes AHNAK2, PVR, SLC7A11, and SREBF1.
• These genes are linked to tumor growth and invasion through metabolic regulatory mechanisms.
• The study presents a connection between lactate metabolism and epigenetic regulation in aggressive BC progression.

Clinical Implications

The findings suggest that targeting glycolysis and histone lactylation may offer new therapeutic strategies for managing aggressive bladder cancer. Understanding the metabolic and epigenetic landscape of BC could lead to the identification of novel prognostic markers.

Conclusion

The study establishes a link between glycolysis and histone lactylation in bladder cancer.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Glycolytic reprogramming in cancer: immune crosstalk, nutrient competition, and supportive care perspectives
2. Frontiers in Oncology, 2026 -- ADGRD1 promotes bladder cancer progression and angiogenesis via the PI3K/AKT/mTOR-mediated pro-angiogenic secretome
3. Frontiers in Immunology, 2026 -- Glycolytic reprogramming in ovarian cancer: mechanisms, immune crosstalk, and therapeutic implications
4. FDA, 2023 -- FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer
5. The ASCO Post — EGFR a Potential Target in Muscle-Invasive Bladder Cancer With Basal-Like Phenotype
6. EAU Pocket Guidelines on Muscle-invasive Bladder Cancer 2026
7. NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer, Version 1.2026
8. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf
9. FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer | FDA
10. AUA 2024: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from JAVELIN Bladder 100 in Subgroups Defined by First-Line Chemotherapy Regimen and Analysis of OS from Start of First-Line Chemotherapy
11. Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274 - PubMed
12. Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274. | Journal of Clinical Oncology
13. Erdafitinib or Chemotherapy in
14. Frontiers | Glycolysis-Mediated H3K18la Modifications Drive Aggressive Bladder Cancer through Metabolic and Epigenetic Reprogramming
15. Hypoxia-induced PYCR1 regulates glycolysis and histone lactylation to promote bladder cancer progres
16. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer - ScienceDirect
17. Lactate and lactylation in cancer | Signal Transduction and Targeted Therapy